Non-Motor Symptom Burdens Are Not Associated with Iron Accumulation in Early Parkinson's Disease: a Quantitative Susceptibility Mapping Study

Chaewon Shin,1 Seon Lee,2 Jee-Young Lee,2 Jung Hyo Rhim,4 and Sun-Won Park4,5

1Department of Neurology, Kyung Hee University Medical Center, Seoul, Korea
2Department of Mechanical and Aerospace Engineering, Seoul National University, Seoul, Korea
3Department of Neurology, Seoul National University-Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea
4Department of Radiology, Seoul National University-Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea
5Department of Radiology, Seoul National University College of Medicine, Seoul, Korea

ABSTRACT

Background: Quantitative susceptibility mapping (QSM) has been used to measure iron accumulation in the deep nuclei of patients with Parkinson's disease (PD). This study examined the relationship between non-motor symptoms (NMSs) and iron accumulation in the deep nuclei of patients with PD.

Methods: The QSM data were acquired from 3-Tesla magnetic resonance imaging (MRI) in 29 patients with early PD and 19 normal controls. The Korean version of the NMS scale (K-NMSS) was used for evaluation of NMSs in patients. The patients were divided into high NMS and low NMS groups. The region-of-interest analyses were performed in the following deep nuclei: red nucleus, substantia nigra pars compacta, substantia nigra pars reticulata, dentate nucleus, globus pallidus, putamen, and head of the caudate nucleus.

Results: Thirteen patients had high NMS scores (total K-NMSS score, mean = 32.1), and 16 had low NMS scores (10.6). The QSM values in the deep were not different among the patients with high NMS scores, low NMS scores, and controls. The QSM values were not correlated linearly with K-NMSS total score after adjusting the age at acquisition of brain MRI.

Conclusion: The study demonstrated that the NMS burdens are not associated with iron accumulation in the deep nuclei of patients with PD. These results suggest that future neuroimaging studies on the pathology of NMSs in PD should use more specific and detailed clinical tools and recruit PD patients with severe NMSs.

Keywords: Parkinson Disease; Iron; Basal Ganglia; Magnetic Resonance Imaging

INTRODUCTION

Iron accumulation in the brain increases with age in the substantia nigra (SN), putamen (PU), globus pallidus (GP), caudate nucleus (CN), and cortex. The accumulation is greater in patients with Parkinson's disease (PD) who exhibit widespread neurodegeneration in the basal ganglia (BG). Neuropathological studies have revealed that iron concentrations are
increased in the SN pars compacta (SNC) and reticulata (SNR) in patients with PD.\textsuperscript{2,3} Although the mechanisms underlying the increased accumulation of iron in patients with PD are unclear, researchers have used various methods to measure the in vivo levels of iron accumulation.\textsuperscript{1}

Iron deposits in the deep nuclei of the brain influence regional magnetic susceptibility, which can be detected with brain magnetic resonance imaging (MRI).\textsuperscript{4} Previous studies using brain MRI in patients with PD have measured the transverse relaxation rates ($R_2$ and $R_2^*$) and revealed that $R_2^*$ was increased in the SNC and related to motor severity.\textsuperscript{5,6} Longitudinal studies have suggested that $R_2^*$ values increase with PD progression.\textsuperscript{7-9} However, $R_2^*$ is limited because it cannot exclude the magnetic susceptibility of the surrounding tissue. To solve this problem, a new method, quantitative susceptibility mapping (QSM), was developed.

Studies that have used QSM to measure iron accumulation in patients with PD have found that magnetic susceptibility was increased in the SNC compared with that in healthy controls,\textsuperscript{10-16} and these increases were also found in patients in the early stage of PD.\textsuperscript{11,13,16} Several studies have also found increased susceptibility in the GP, red nucleus (RN), and thalamus of patients with PD.\textsuperscript{10,11,16} As expected, QSM measures are more precise than $R_2^*$.\textsuperscript{12-14} The QSM values in the SNC of patients with PD increase with disease duration\textsuperscript{12,16} and correlate with disease severity.\textsuperscript{10,12,16} In addition, QSM values are increased in the dentate nucleus (DN) in patients with the tremor dominant subtype of PD.\textsuperscript{17} A recent study reported that the Movement Disorder Society-sponsored revision of the Unified PD Rating Scale (MDS-UPDRS) Part I (non-motor experiences in daily life) scores positively correlated with magnetic susceptibility in the GP, CN, SN, and PUs.\textsuperscript{10}

Interest is increasing in the non-motor symptoms (NMSs) of patients with PD.\textsuperscript{18,19} Some NMSs precede the motor symptoms and would be used for diagnosis of early or prodromal stage of PD. Furthermore, several early NMSs are related to the prognosis of the patients with PD.\textsuperscript{20} However, because few studies have evaluated the relationships of the in vivo pathology and NMSs, the current understanding of the pathophysiology of NMSs depends on indirect anatomic correlations from post-mortem pathology studies.\textsuperscript{21} Based on neuroanatomic knowledge, NMSs originate from various brain lesions beyond the motor circuit in the BG. Hyposmia is related to the anterior olfactory nucleus; depression and sleep disorders are related to the pontine nuclei such as the locus ceruleus, raphe, lateral tegmental nuclei; executive, emotional, and behavior problems are related to the nucleus basalis Meynert and amygdala; dementia and psychosis are related to the neocortex. According to the current pathologic staging system for PD, the more extensive pathologic changes exist, the severer pathology can be found.\textsuperscript{22} Therefore, patients with more NMSs probably have more extensive and severe pathology in the brain.

In this study, we assumed that wider iron accumulation, which reflects pathologic changes, would be observed in the brain of patients with more NMSs. To prove this hypothesis, we examined the relationship between NMSs and iron accumulation in the deep nuclei, which was measured with QSM, in patients with PD.

**METHODS**

**Patients and clinical assessments**
Participants eligible for this study were patients who were diagnosed with PD and who underwent brain MRI within 5 years of the onset of motor symptoms at the Seoul National University-Seoul Metropolitan Government (SNU-SMG) Boramae Medical Center. The
diagnosis of PD was confirmed by movement disorder specialists using the UK brain bank clinical diagnosis criteria. Patients with other neurodegenerative diseases or secondary brain lesions were excluded. Control candidates were selected from the brain MRI database of the SNU-SMG Boramae Medical Center. Individuals with a history of neurological diseases or abnormalities on brain MRI were excluded from the control group.

The clinical data were acquired with retrospective reviews of medical records. The demographic data included sex, age at acquisition of brain MRI, and age at the onset of motor symptoms. Disease duration was defined as the time from the age at the onset of motor symptoms to the age at acquisition of brain MRI. The severity of PD was evaluated with the Hoehn and Yahr (HY) stage, and MDS-UPDRS part III scores that were evaluated within 1 month of the acquisition of brain MRI. The levodopa-equivalent daily dose (LEDD) was calculated by reviewing the medication history of each patient. The NMS burden of the patients were evaluated using the Korean version of the NMS scale (K-NMSS). The patients were further divided into a high NMS group and low NMS group according to the cut-off value of 20 in K-NMSS. This value was adopted from the comprehensive grading system of NMS severity in PD, in which the value discriminates mild vs. more severe NMS burden in patients with PD.

**MRI protocol and data reconstruction**

All patients were scanned with 3-Tesla brain MRI (Achieva 3.0T; Koninklijke Philips N.V., Amsterdam, the Netherlands) using an 8-channel head coil. All scans were in the axial plane. A three-dimensional single gradient-echo sequence was acquired; the parameters were the following: echo time = 25.7–28.5 ms; repetition time = 18.2–20.0 ms; field of view = 200 × 200 mm; matrix = 256 × 256; slice thickness = 2 mm, no gap; and flip angle = 10°. The voxel size was same (0.390625, 0.390625, 2) for all subjects. The entire slices of 3D scan data were reconstructed in QSM images using a susceptibility tensor imaging software suite (version 2.2, Updated on Jan. 8, 2014; Brain Imaging & Analysis Center, Durham, NC, USA). All other parameters which are required for the calculation of susceptibility were the same; Tol_LSQR was 0.01, D2_thres was 0.1, and Max_iter was 100.

**Region-of-interest analysis**

The region-of-interest (ROIs) were manually segmented on the reconstructed QSM images by one investigator using ITK-SNAP (www.itksnap.org). No normalization on the brain size was done. The targeted deep nuclei were the following: SNc, SNr, RN, GP, DN, PU, and head of the CN (HCN, Fig 1). The ROIs were drawn on the slices that covered the SNc, SNr, RN, and DN. We selected the 2–5 most representative slices of the GP, HCN, and PU to minimize the influence of the surrounding structures due to unclear margins. The QSM values of deep nuclei of the patients and controls were calculated separately by averaging the values of selected ROIs.

**Statistical analyses**

All statistical analyses were performed with SPSS (version 21.0; IBM Corporation, Armonk, NY, USA). Non-parametric tests (Fisher’s exact and Kruskal-Wallis tests) were used to compare the demographics of the patients with high and low NMS scores and controls. Mann-Whitney U tests were used to compare the clinical data between the patients with high and low NMS scores. The QSM susceptibility value in each ipsilateral and contralateral deep nucleus to the dominant side of motor symptoms of the patients was compared with mean QSM value of left and right deep nuclei of controls with Kruskal-Wallis tests. Bonferroni correction was used for multiple comparison (P value threshold = 0.025). The Pearson’s
partial correlation analyses adjusting the age at acquisition of brain MRI were performed to evaluate the linear correlations between the clinical characteristics and QSM data in the entire patient group. Two-tailed $P$ values less than 0.05 were considered statistically significant.

**Ethics statement**
This study protocol was approved by the Institutional Review Board of the Seoul National University-Seoul Metropolitan Government Boramae Medical Center (No. 26-2016-107). A waiver of informed consent met the requirements and was granted.

**RESULTS**

**Clinical data comparisons**
The detailed clinical characteristics are presented in Table 1 (see supplemental data for individual clinical and QSM data; Supplementary Tables 1 and 2). The percentage of males and age at acquisition of brain MRI did not differ among the patients with high and low NMS scores and controls. The patients with high and low NMS scores did not differ in the age at the onset of motor symptoms, disease duration, HY stage, MDS-UPDRS III score, and LEDDs.

| Characteristics                  | Patients with high NMS scores (n = 13) | Patients with low NMS scores (n = 16) | Controls (n = 19) | $P$ value |
|----------------------------------|---------------------------------------|---------------------------------------|-------------------|-----------|
| Percentage of males (frequency)  | 23.1 (3)                               | 31.3 (5)                               | 26.3 (5)          | 0.922     |
| Age at acquisition of brain MRI, yr | 69.8 ± 11.2                           | 71.4 ± 6.8                            | 67.6 ± 8.0        | 0.433     |
| Age at the onset of motor symptoms, yr | 67.9 ± 11.4                           | 70.4 ± 6.5                            | 0.792             |
| HY stage                         | 2 (1, 2.5)                             | 1.75 (1, 2)                            | 0.200             |
| LEDD                             | 199.9 ± 230.7                          | 150.0 ± 200.0                         | 0.542             |
| MDS-UPDRS part III               | 20.9 ± 10.9                            | 19.7 ± 10.5                           | 0.661             |
| K-NMSS total score              | 32.1 ± 11.9                            | 10.6 ± 4.2                            | < 0.001           |
| Interval of K-NMSS and brain MRI, day | 14.4 ± 10.3                           | 13.4 ± 16.0                           | 0.455             |

Data not otherwise specified are presented as mean ± standard deviation. Data are presented as percentage (frequency) or median (minimum, maximum).

NMS = non-motor symptom, MRI = magnetic resonance imaging, HY = Hoehn and Yahr, LEDD = levodopa-equivalent daily dose, MDS-UPDRS = Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale, K-NMSS = Korean version of the Non-motor Symptoms Scale.
The comparisons of the scores for each item on the K-NMSS between the patients with high and low NMS scores are presented in Table 2. Patients with high NMS scores had higher scores for dizziness, fatigue, difficulty falling asleep, restless legs, nervous feeling, urinary urgency, frequency, nocturia, and weight change.

**ROI analysis results**

The regional QSM values were compared among the patients with high and low NMS scores and controls (Table 3). There were no significant differences in the QSM values of all deep nuclei among the patients with high and low NMS scores and controls.

**QSM and clinical data correlations**

In the partial correlation analyses adjusting the age at acquisition of brain MRI, LEDD was correlated linearly with the QSM values of ipsilateral SNc \((r = -0.426; P = 0.024)\) and

---

**Table 2.** Detailed comparisons of the patients with high and low K-NMSS scores

| Characteristics                  | Patients with high NMS scores (n = 13) | Patients with low NMS scores (n = 16) | P value |
|----------------------------------|---------------------------------------|---------------------------------------|---------|
| **Domain 1 (cardiovascular)**    |                                       |                                       |         |
| Dizziness                        | 1.5 ± 1.7                             | 0.3 ± 0.6                             | 0.002   |
| Falling due to fainting          | 0                                     | 0                                     | 1.000   |
| **Domain 2 (sleep/fatigue)**     |                                       |                                       |         |
| Daytime sleep                    | 0.7 ± 1.2                             | 0.4 ± 0.6                             | 0.747   |
| Fatigue                          | 1.3 ± 1.8                             | 0.2 ± 0.4                             | 0.027   |
| Difficulty falling asleep        | 3.7 ± 2.7                             | 0.8 ± 1.4                             | 0.001   |
| Restless legs                    | 1.1 ± 2.5                             | 0                                     | 0.019   |
| **Domain 3 (mood/cognition)**    |                                       |                                       |         |
| Loss of interest in surroundings  | 1.1 ± 1.8                             | 0.4 ± 0.7                             | 0.337   |
| Lack of motivation               | 0.8 ± 0.9                             | 0.3 ± 0.7                             | 0.081   |
| Nervous feeling                  | 1.5 ± 1.4                             | 0.5 ± 0.6                             | 0.035   |
| Depression                       | 1.4 ± 1.4                             | 1.0 ± 1.7                             | 0.313   |
| Flat mood                        | 1.3 ± 1.3                             | 0.6 ± 1.0                             | 0.052   |
| Lack of pleasure                 | 0.8 ± 1.3                             | 0.1 ± 0.3                             | 0.079   |
| **Domain 4 (perceptual/hallucination)** |                                 |                                       |         |
| Hallucinations                   | 0.2 ± 0.4                             | 0                                     | 0.110   |
| Delusions                        | 0                                     | 0                                     | 1.000   |
| Double vision                    | 0.3 ± 0.6                             | 0.1 ± 0.3                             | 0.187   |
| **Domain 5 (attention/memory)**  |                                       |                                       |         |
| Poor concentration               | 1.2 ± 1.0                             | 0.8 ± 0.9                             | 0.165   |
| Forgetfulness of past events     | 1.2 ± 1.1                             | 0.9 ± 0.9                             | 0.661   |
| Forgetfulness for making plans   | 0.7 ± 1.0                             | 0.4 ± 0.6                             | 0.499   |
| **Domain 6 (gastrointestinal tract)** |                                 |                                       |         |
| Drooling                         | 0.5 ± 0.9                             | 0.4 ± 0.8                             | 0.517   |
| Dysphagia                        | 0.3 ± 0.9                             | 0                                     | 0.110   |
| Constipation                     | 2.5 ± 3.0                             | 1.1 ± 1.2                             | 0.400   |
| **Domain 7 (urinary)**           |                                       |                                       |         |
| Urgency                          | 2.1 ± 2.3                             | 0.5 ± 0.8                             | 0.038   |
| Frequency                        | 1.8 ± 2.0                             | 0.3 ± 0.8                             | 0.011   |
| Nocturia                         | 2.4 ± 1.5                             | 1.3 ± 1.1                             | 0.041   |
| **Domain 8 (sexual)**            |                                       |                                       |         |
| Altered interest in sex          | 0.6 ± 1.7                             | 0                                     | 0.110   |
| Sexual problems                  | 0.5 ± 1.6                             | 0                                     | 0.110   |
| **Domain 9 (miscellaneous)**     |                                       |                                       |         |
| Unexplained pain                 | 0.5 ± 0.9                             | 0.1 ± 0.3                             | 0.082   |
| Change in ability to taste or smell | 0.9 ± 1.4                             | 0.3 ± 0.6                             | 0.181   |
| Weight change                    | 0.4 ± 0.7                             | 0                                     | 0.019   |
| Excessive sweating               | 0.8 ± 1.5                             | 0.1 ± 0.3                             | 0.165   |

Data not otherwise specified are presented as mean ± standard deviation.

K-NMSS = Korean version of the Non-motor Symptoms Scale, NMS = non-motor symptom.
ipsilateral SNr \( (r = -0.518; \ P = 0.005) \). Disease duration, HY stage, MDS-UPDRS part III score, and K-NMSS total score were not correlated with regional QSM values.

**DISCUSSION**

This study was the first study that evaluated the relationship between NMSs and regional iron accumulation in PD using a detailed NMS questionnaire and QSM. In contrast with our hypothesis, the QSM values in deep nuclei of the patients with PD, including SNc, were not different from the values of the controls. The QSM values of ipsilateral SNc and SNr were negatively correlated with LEDD.

Several possible reasons may explain these results. First, it can be assumed that different pathologies, which are not confined to the deep nuclei in this study, resulted in NMSs of patients with PD. This is consistent with a previous study that evaluated the relationship between the striatal dopamine level and NMS burden. \(^{30}\) Second, most of the patients who participated in this study had a very early stage of PD, hence the NMS burden was not severe. As a result, the pathological changes in the brain associated with this NMS burden may not be evident. Finally, the K-NMSS is a collection of heterogeneous NMSs possibly originated from various brain regions. The definition of NMS burden in this study is a clinically meaningful distinction\(^{27}\) but a simple sum without consideration of the heterogeneous nature of K-NMSS. Therefore, the association with the iron accumulation in a specific region of the brain may not be properly reflected. Neuroimaging studies on the brain pathology of NMSs in the future would be better to use specific and detailed clinical evaluation tools rather than K-NMSS.

---

**Table 3. Regional differences in the susceptibility values in patients with PD and controls**

| Nucleus | Susceptibility value, ppm | Patients with high NMS scores (n = 13) | Patients with low NMS scores (n = 16) | Controls (n = 19) | \( P \) value* |
|---------|---------------------------|----------------------------------------|----------------------------------------|------------------|---------------|
| RN      |                           |                                        |                                        |                  |               |
| Ipsilateral | 0.104 ± 0.021             | 0.100 ± 0.040                         | 0.092 ± 0.023                         | 0.484            |               |
| Contralateral | 0.103 ± 0.017             | 0.104 ± 0.038                         | 0.307                                 |                  |               |
| SNc     |                           |                                        |                                        |                  |               |
| Ipsilateral | 0.128 ± 0.030             | 0.118 ± 0.048                         | 0.121 ± 0.032                         | 0.759            |               |
| Contralateral | 0.131 ± 0.024             | 0.133 ± 0.054                         | 0.694                                 |                  |               |
| SNr     |                           |                                        |                                        |                  |               |
| Ipsilateral | 0.123 ± 0.029             | 0.127 ± 0.048                         | 0.115 ± 0.039                         | 0.739            |               |
| Contralateral | 0.133 ± 0.028             | 0.128 ± 0.052                         | 0.470                                 |                  |               |
| DN      |                           |                                        |                                        |                  |               |
| Ipsilateral | 0.100 ± 0.037             | 0.096 ± 0.020                         | 0.095 ± 0.023                         | 0.828            |               |
| Contralateral | 0.101 ± 0.029             | 0.090 ± 0.018                         | 0.423                                 |                  |               |
| GP      |                           |                                        |                                        |                  |               |
| Ipsilateral | 0.141 ± 0.029             | 0.136 ± 0.040                         | 0.134 ± 0.036                         | 0.825            |               |
| Contralateral | 0.143 ± 0.028             | 0.140 ± 0.037                         | 0.794                                 |                  |               |
| PU      |                           |                                        |                                        |                  |               |
| Ipsilateral | 0.109 ± 0.042             | 0.103 ± 0.046                         | 0.099 ± 0.035                         | 0.851            |               |
| Contralateral | 0.111 ± 0.043             | 0.104 ± 0.045                         | 0.781                                 |                  |               |
| HCN     |                           |                                        |                                        |                  |               |
| Ipsilateral | 0.070 ± 0.021             | 0.064 ± 0.019                         | 0.061 ± 0.022                         | 0.497            |               |
| Contralateral | 0.068 ± 0.024             | 0.071 ± 0.025                         | 0.401                                 |                  |               |

Data are presented as mean ± standard deviation.

PD = Parkinson’s disease, NMS = non-motor symptom, RN = red nucleus, SNc = substantia nigra pars compacta, SNr = substantia nigra pars reticulata, DN = dentate nucleus, GP = globus pallidus, PU = putamen, HCN = head of the caudate nucleus.

*The Kruskal-Wallis test with Bonferroni correction was used to test for statistical significance. Uncorrected \( P \) value was presented.
In contrast with previous studies, the QSM values in the SNc were not increased in patients with early PD.\textsuperscript{11,13,16} The mean disease durations of the patients with high and low NMS scores in our study were 1.9 years and 1.0 years, respectively, which is much shorter than those reported in previous studies (mean 2.7–4.6 years).\textsuperscript{11,13,16} Therefore, the patients selected in this study were a purer group of patients with very early stage of PD than those recruited in previous studies. On the other hands, the small number of participants in this study might have resulted in the inability to find statistical differences. For example, the QSM value in the contralateral SNc showed a tendency to be increased in the patients compared with the controls. Taken together, these observations suggest that the diagnostic accuracy of the QSM values in patients in the very early or prodromal stage of PD needs to be verified in large numbers of patients.

This study had several limitations. First, the generalization of our results is limited because inferential statistics were not used due to the small number of participants. Second, the ROIs were not drawn by independent investigators, and the reliability and reproducibility of the ROI analysis were not confirmed in this study. Third, the diagnosis of PD was based on clinical criteria without pathologic confirmation,\textsuperscript{23} hence the QSM results would be influenced. Forth, the interval from K-NMSS to the acquisition of brain MRI was not consistent in patients, which may confound the correlation. Finally, the controls were not evaluated by a neurologist, and unknown neurodegenerative diseases could be present in the control group.

In conclusion, the study demonstrated that the NMS burdens are not associated with iron accumulation in the deep nuclei of patients with PD. These results suggest that future neuroimaging studies on the pathology of NMSs in PD should use more specific and detailed clinical tools and recruit PD patients with severe NMSs.

**SUPPLEMENTARY MATERIALS**

**Supplementary Table 1**
Individual data of the patients and controls

[Click here to view](#)

**Supplementary Table 2**
Description of the variables in Supplementary Table 1

[Click here to view](#)

**REFERENCES**

1. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. *Lancet Neurol* 2014;13(10):1045-60.

2. Dexter DT, Wells FR, Agid F, Agid Y, Lees Al, Jenner P, et al. Increased nigral iron content in postmortem parkinsonian brain. *Lancet* 1987;2(8569):1219-20.

3. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. *J Neurochem* 1989;52(2):515-20.
4. Li W, Wu B, Batrachenko A, Bancroft-Wu V, Morey RA, Shashi V, et al. Differential developmental trajectories of magnetic susceptibility in human brain gray and white matter over the lifespan. *Hum Brain Mapp* 2014;35(6):2698-713.

5. Rossi M, Ruottinen H, Soimakallio S, Elovaara I, Dastidar P. Clinical MRI for iron detection in Parkinson's disease. *Clin Imaging* 2013;37(4):631-6.

6. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. *Neurology* 2008;70(16 Pt 2):1411-7.

7. Wieler M, Gee M, Martin WR. Longitudinal midbrain changes in early Parkinson’s disease: iron content estimated from R2'/MRI. *Parkinsonism Relat Disord* 2015;21(3):179-83.

8. Rossi ME, Ruottinen H, Saunamäki T, Elovaara I, Dastidar P. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson’s disease in the initial stages. *Acad Radiol* 2014;21(1):64-71.

9. Ulla M, Bonny JM, Ouchchane L, Rieu I, Claise B, Durif F. Is R2’ a new MRI biomarker for the progression of Parkinson’s disease? A longitudinal follow-up. *PLoS One* 2013;8(3):e57904.

10. Langkammer C, Pirpamer L, Seiler S, Deistung A, Schweser F, Franthal S, et al. Quantitative susceptibility mapping in Parkinson’s disease. *PLoS One* 2016;11(9):e0162460.

11. Guan X, Xuan M, Gu Q, Huang P, Liu C, Wang N, et al. Regionally progressive accumulation of iron in Parkinson’s disease as measured by quantitative susceptibility mapping. *NMR Biomed* 2017;30(4):e3489.

12. Du G, Liu T, Lewis MM, Kong L, Wang Y, Connor J, et al. Quantitative susceptibility mapping of the midbrain in Parkinson’s disease. *Mov Disord* 2016;31(3):317-24.

13. Murakami Y, Kakeda S, Watanabe K, Ueda I, Ogasawara A, Moriya J, et al. Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease. *AJNR Am J Neuroradiol* 2015;36(6):1102-8.

14. Barbosa JH, Santos AC, Tumas V, Liu M, Zheng W, Haacke EM, et al. Quantifying brain iron deposition in patients with Parkinson’s disease using quantitative susceptibility mapping, R2 and R2'. *Magn Reson Imaging* 2015;33(5):559-65.

15. Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schäfer A, Peters AM, et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson’s disease. *J Magn Reson Imaging* 2012;35(1):48-55.

16. He N, Ling H, Ding B, Huang J, Zhang Y, Zhang Z, et al. Region-specific disturbed iron distribution in early idiopathic Parkinson’s disease measured by quantitative susceptibility mapping. *Hum Brain Mapp* 2015;36(11):4407-20.

17. He N, Huang P, Ling H, Langley J, Liu C, Ding B, et al. Dentate nucleus iron deposition is a potential biomarker for tremor-dominant Parkinson's disease. *NMR Biomed* 2017;30(4):e3554.

18. Kwon DY, Koh SB, Lee JH, Park HK, Kim HJ, Shin HW, et al. The KMDS-NATION Study: Korean Movement disorders society multicenter assessment of non-motor symptoms and quality of life in Parkinson’s disease NATION Study Group. *J Clin Neurol* 2016;12(4):393-402.

19. Cheon SM, Park MJ, Kim WJ, Kim JW. Non-motor off symptoms in Parkinson’s disease. *J Korean Med Sci* 2009;24(2):311-4.

20. Lo RV, Tanner CM, Albers KB, Leimpepeter AD, Fross RD, Bernstein AL, et al. Clinical features in early Parkinson disease and survival. *Arch Neurol* 2009;66(11):1353-8.

21. Jellinger KA. Neuropathobiology of non-motor symptoms in Parkinson disease. *J Neural Transm (Vienna)* 2015;122(10):1429-40.
22. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. *Neurobiol Aging* 2003;24(2):197-211.

23. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 1992;55(3):181-4.

24. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* 2008;23(15):2129-70.

25. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. *Mov Disord* 2010;25(15):2649-53.

26. Koh SB, Kim JW, Ma HI, Ahn TB, Cho JW, Lee PH, et al. Validation of the korean-version of the nonmotor symptoms scale for Parkinson’s disease. *J Clin Neurol* 2012;8(4):276-83.

27. Ray Chaudhuri K, Rojo JM, Schapira AH, Brooks DJ, Stocchi F, Odin P, et al. A proposal for a comprehensive grading of Parkinson’s disease severity combining motor and non-motor assessments: meeting an unmet need. *PLoS One* 2013;8(2):e57221.

28. Li W, Avram AV, Wu B, Xiao X, Liu C. Integrated Laplacian-based phase unwrapping and background phase removal for quantitative susceptibility mapping. *NMR Biomed* 2014;27(2):219-27.

29. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. *Neuroimage* 2006;31(3):1116-28.

30. Chung SJ, Lee JJ, Ham JH, Ye BS, Lee PH, Sohn YH. Striatal dopamine depletion patterns and early non-motor burden in Parkinsons disease. *PLoS One* 2016;11(8):e0161316.